+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
Age: 18Years +
All Genders
ID04421820

Study of BOLD-100 Combined With FOLFOX Chemotherapy With or Without Bevacizumab for Advanced Gastrointestinal Cancers

Led by Bold Therapeutics, Inc. · Updated on 2026-10-28

220

Participants Needed

28

Research Sites

26 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating BOLD-100, an intravenous ruthenium-based small molecule drug, in combination with FOLFOX chemotherapy with or without Bevacizumab for treating advanced gastrointestinal cancers such as colorectal, pancreatic, gastric cancers, and cholangiocarcinoma. This Phase 1b2a non-randomized study includes a dose escalation phase to assess safety and tolerability, followed by a cohort expansion phase focusing on patients with advanced solid tumors. The study aims to understand BOLD-100s potential when combined with standard chemotherapy regimens. Participants receive BOLD-100 combined with FOLFOX chemotherapy, with or without Bevacizumab, in different dose levels including 500 mgm2 and 625 mgm2. The study includes multiple arms, some closed to enrollment and others open to patients with colorectal cancer who are oxaliplatin naive and have had only one prior metastatic treatment. Participants are randomized in Arm VII to receive one of two doses of BOLD-100 plus FOLFOX Bevacizumab or FOLFOX Bevacizumab alone. Throughout the study, participants undergo assessments for adverse events, dose-limiting toxicities, physical exams, ECGs, laboratory tests, and performance status. Quality of life questionnaires focusing on general and neuropathy-related aspects are completed by those in Arm VII. Researchers measure progression-free survival, overall response rate, and overall survival. The study also monitors pharmacokinetics and biomarkers during treatment. Participation continues until approximately two weeks after the last treatment, with ongoing safety and efficacy evaluations.

CONDITIONS

Brief Title

BOLD-100 in Combination With FOLFOX With or Without Bevacizumab for the Treatment of Advanced, Solid Tumours

Research Team

M

Michelle Jones

J

Jim Pankovich

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here